Zhe-Jun Liu

ADAM17 as a proteolytic rheostat linking inflammation, tissue repair, and failure of inflammatory resolution in liver injury and fibrosis.

This framework suggests that therapeutic strategies should move beyond broad ADAM17 inhibition toward context-, cell-, or substrate-selective modulation that limits pathogenic signaling while preserving inflammation-resolving and tissue-repair functions.